Cutaneous plasmacytosis (CP) is a rare disorder of unknown aetiology characterized by the proliferation of mature plasma cells in the skin and polyclonal hypergammaglobulinaemia. CP is associated with elevated IL-6. Anti-IL-6 therapy has not been reported as a treatment for idiopathic CP. We present the case of a woman with idiopathic CP who was treated successfully with tocilizumab, a monoclonal anti-IL-6 receptor antibody. The patient experienced improvement in cutaneous lesions and subjective symptoms after 2 months on tocilizumab.
No takes yet. Share an insight, caveat, or question.
Daftary et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: